| Date: | 2010-05-05 |
| Biotech partner: | EndoCeutics (Canada) |
| Pharma Partner: | Bayer Schering Pharma (Germany) |
| Type of agreement: | * licensing * manufacturing * commercialization/ distribution * development * marketing/ promotion |
| Compound: | Vaginorm® (intra-vaginal application of dehydroepiandrosterone-DHEA) |
| Disease area: | vulvovaginal atrophy and female sexual dysfunction in postmenopausal women |
| Development phase: | A Phase III clinical program for Vaginorm in the treatment of symptoms of vulvovaginal atrophy and female sexual dysfunction in postmenopausal women has been initiated. |
| Nature of the agreement: | Bayer Schering Pharma has signed a global exclusive cooperation agreement with the Canadian company EndoCeutics for the development and commercialization of Vaginorm®, an intra-vaginal application of dehydroepiandrosterone (DHEA). EndoCeutics is responsible for conducting the Phase III studies for Vaginorm®. Thereafter, Bayer will be responsible for its registration and commercialization. Under the terms of the agreement, EndoCeutics grants Bayer a worldwide, exclusive license to develop, manufacture and commercialize Vaginorm®. |
| Financial terms of the agreement: | Financial details were not disclosed. |
